Statistical Analysis
Statistical testing to measure the association of these drugs with the specified cardiac events of interest was performed using disproportionality signal analysis. These were presented as reporting odds ratios (RORs) of reported cardiac adverse events concomitant with the use of a newly approved multiple myeloma agent compared to the same reported adverse events within the entire database of pharmaceuticals within FAERS. The ROR was considered significant when the lower limit of the 95% CI was >1.0.